

**THE AMENDMENTS**

**In The Claims:**

1-44. (Cancelled)

45. (Currently Amended) [[A]] An isolated fragment peptide comprising consisting of a fragment of the a frameshift polypeptide according to Claim 44, selected from the group consisting of TAF1b (-1) ORF, SEQ ID NO: 20; TAF1b (+1) ORF, SEQ ID NO: 21; HT001 (-1) ORF, SEQ ID NO: 2; HT001 (+1) ORF, SEQ ID NO: 3; and HT001 (-2) ORF, SEQ ID NO: 118; wherein said fragment peptide comprises at least 3 amino acids of a mutated part of the frameshift polypeptide and has a length of at least 15 amino acids.

46. (Previously Presented) The fragment peptide according to Claim 45, wherein said fragment peptide has an immunogenic portion with a length of about 10-20 amino acids.

47. (Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 20 and the three amino acids are TIL.

48. (Withdrawn-Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 21 and the three amino acids are KQY.

49. (Withdrawn-Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 2 and the three amino acids are GRR.

50. (Withdrawn-Currently Amended) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 3 and the three amino acids are KAE.

51. (Cancelled)

52. (Previously Presented) A pharmaceutical composition comprising the fragment peptide according to Claim 45 and a physiologically acceptable carrier.

53. (Previously Presented) A pharmaceutical composition comprising the fragment peptide according to Claim 47 and a physiologically acceptable carrier.

54. (Withdrawn) A pharmaceutical composition comprising the fragment peptide according to Claim 48 and a physiologically acceptable carrier.

55. (Withdrawn) A pharmaceutical composition comprising the fragment peptide according to Claim 49 and a physiologically acceptable carrier.

56. (Withdrawn) A pharmaceutical composition comprising the fragment peptide according to Claim 50 and a physiologically acceptable carrier.

57. (Cancelled)

58. (Previously Presented) A diagnostic kit comprising the fragment peptide according to Claim 45 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.

59. (Previously Presented) A diagnostic kit comprising the fragment peptide according to Claim 47 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.

60. (Withdrawn) A diagnostic kit comprising the fragment peptide according to Claim 48 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and

additional reagents and buffers for carrying out the detection reactions.

61. (Withdrawn) A diagnostic kit comprising the fragment peptide according to Claim 49 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.

62. (Withdrawn) A diagnostic kit comprising the fragment peptide according to Claim 50 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.

63-79. (Cancelled)

80. (New) The fragment peptide according to Claim 45, wherein the frameshift polypeptide has the amino acid sequence of SEQ ID NO: 118 and the three amino acids are AEE.

81. (New) A pharmaceutical composition comprising the fragment peptide according to Claim 80 and a physiologically acceptable carrier.

82. (New) A diagnostic kit comprising the fragment peptide according to Claim 80 as a reagent for detecting antibodies or cells specifically recognizing the fragment peptide, and additional reagents and buffers for carrying out the detection reactions.